Zydus Cadila Gets First Patch Approval Amid Push Into US

A generic rival to Novartis’ Exelon extended-release treatment for dementia marks Zydus Cadila’s first transdermal patch approval in the US, furthering the Indian firm’s strategy of targeting more complex delivery forms.

Patch
Zydus Cadila has extended its US generics offering with its first approval for a transdermal patch • Source: Shutterstock

Zydus Cadila has expanded its rapidly growing roster of generic approvals in the US with Food and Drug Administration (FDA) clearance for its first transdermal patch, a rivastigmine transdermal system for treating dementia associated with Alzheimer’s and Parkinson’s diseases.

Both US patents listed against the reference brand, Novartis’ Exelon Patch, in the FDA’s Orange Book expired in January this...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin